BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

831 related articles for article (PubMed ID: 2657231)

  • 1. Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia.
    Wisniewski D; Strife A; Arlin Z; Knowles R; Lambek C; Gulati S; McHendry B; McKenzie S; Clarkson B
    Leukemia; 1989 Jun; 3(6):446-52. PubMed ID: 2657231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-clinical evaluation of anti-lacto-N-fucopentaose III (CD15) monoclonal antibodies for ex vivo bone marrow purging in acute myeloid leukemia.
    Guyotat D; Shi ZH; Campos L; Rabat M; Bonnier S; Poncelet P; Laurent JC; Fiere D
    Bone Marrow Transplant; 1990 Dec; 6(6):385-90. PubMed ID: 1982926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of anti-myeloid antibodies on the generation of hematopoietic colony-forming units in long-term bone marrow culture.
    Ball ED; Keefe KA; McDermott JM
    Bone Marrow Transplant; 1989 May; 4(3):309-15. PubMed ID: 2659116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells.
    Griffin JD; Linch D; Sabbath K; Larcom P; Schlossman SF
    Leuk Res; 1984; 8(4):521-34. PubMed ID: 6590930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combinations for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia.
    Stiff PJ; Schulz WC; Bishop M; Marks L
    Blood; 1991 Jan; 77(2):355-62. PubMed ID: 1985700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells.
    Roy DC; Griffin JD; Belvin M; Blättler WA; Lambert JM; Ritz J
    Blood; 1991 Jun; 77(11):2404-12. PubMed ID: 2039821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures.
    La Russa VF; Griffin JD; Kessler SW; Cutting MA; Knight RD; Blattler WA; Lambert JM; Wright DG
    Exp Hematol; 1992 May; 20(4):442-8. PubMed ID: 1373688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of adult human marrow hematopoietic progenitors highly enriched by two-color cell sorting with My10 and major histocompatibility class II monoclonal antibodies.
    Lu L; Walker D; Broxmeyer HE; Hoffman R; Hu W; Walker E
    J Immunol; 1987 Sep; 139(6):1823-9. PubMed ID: 3114377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic phenotype of chronic granulocytic leukaemia progenitor cells in chronic phase and in blastic transformation characterized by means of monoclonal antibodies.
    Robak T
    Arch Immunol Ther Exp (Warsz); 1988; 36(4):471-85. PubMed ID: 3074744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotyping of acute myelocytic leukemia (AML) progenitors: an approach for tracing minimal numbers of AML cells among normal bone marrow.
    Delwel R; van Gurp R; Bot F; Touw I; Löwenberg B
    Leukemia; 1988 Dec; 2(12):814-9. PubMed ID: 3199876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of the 124-kd antigen defined by monoclonal antibody AML-1-99 on normal and leukemic myeloid cells.
    Howell AL; Miller R; Keefe KA; McIntyre OR; Stockner M; Sullivan R; Hibbert SR; Noelle RJ; Ball ED
    Exp Hematol; 1988 Mar; 16(3):176-83. PubMed ID: 3422192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination.
    Lemoli RM; Gasparetto C; Scheinberg DA; Moore MA; Clarkson BD; Gulati SC
    Blood; 1991 Apr; 77(8):1829-36. PubMed ID: 2015406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies against human hemopoietic cells and the separation of progenitor cells from bone marrow.
    Mouchiroud G; Berthier R; Newton IA; Chapel A; Hollard D
    Exp Hematol; 1985 Jul; 13(6):566-73. PubMed ID: 3996493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of monoclonal antibodies in the antigenic characteristics of normal myeloid progenitor cells and clonogenic blasts in acute myeloid leukaemia.
    Robak T
    Arch Immunol Ther Exp (Warsz); 1988; 36(1):71-84. PubMed ID: 3233065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proliferative response of human acute myeloid leukemia cells and normal marrow enriched progenitor cells to human recombinant growth factors IL-3, GM-CSF and G-CSF alone and in combination.
    Lemoli RM; Gulati SC; Strife A; Lambek C; Perez A; Clarkson BD
    Leukemia; 1991 May; 5(5):386-91. PubMed ID: 1709711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.
    Broxmeyer HE; Williams DE; Lu L; Cooper S; Anderson SL; Beyer GS; Hoffman R; Rubin BY
    J Immunol; 1986 Jun; 136(12):4487-95. PubMed ID: 3086433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth of CD34+ acute myeloblastic leukemia colony-forming cells in response to recombinant hematopoietic growth factors.
    Carlo-Stella C; Mangoni L; Almici C; Frassoni F; Fiers W; Rizzoli V
    Leukemia; 1990 Aug; 4(8):561-6. PubMed ID: 1697011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia.
    Wisniewski D; Strife A; Atzpodien J; Clarkson BD
    Cancer Res; 1987 Sep; 47(18):4788-94. PubMed ID: 3040231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of in vitro inhibition of etoposide (VP16) on leukemic and normal myeloid, erythroid clonogenic cells.
    Lagneaux L; Marie JP; Delforge A; Socquet M; Thevenin D; Zittoun R; Stryckmans P
    Exp Hematol; 1989 Aug; 17(7):843-6. PubMed ID: 2753092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.